ERBB2 and cancer: Fourth, approximately 62% of the patients with ERBB2+ cancer had missing values in the ERBB2/CEP17 ratio, so patients with these data available might not be representative, which limits the external generalizability of our findings on the ERBB2/CEP17 ratio.